A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
← catalyst calendarSponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
280actual
Sites
102
Countries
Australia, Austria, Bulgaria +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-21 | actual | When the study began enrolling |
| Primary completion | 2024-11-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-10 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Inflammatory Bowel Diseases
- Colitis, Ulcerative
Interventions
- Drug: MORF-057 — also filed as LY4268989
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)
measured Week 12
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-03-27 · 2.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-09-18 · 761 KB · SAP_001.pdf
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed